Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients

Improved therapies are urgently needed for patients with diffuse large B cell lymphoma (DLBCL). Success using immune checkpoint inhibitors and chimeric antigen receptor T cell technology has fuelled demand for validated cancer epitopes. Immunogenic cancer testis antigens (CTAs), with their widesprea...

Descripción completa

Detalles Bibliográficos
Autores principales: Ait-Tahar, Kamel, Anderson, Amanda P., Barnardo, Martin, Collins, Graham P., Hatton, Chris S. R., Banham, Alison H., Pulford, Karen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5674480/
https://www.ncbi.nlm.nih.gov/pubmed/29204156
http://dx.doi.org/10.1155/2017/6527306

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5674480/
https://www.ncbi.nlm.nih.gov/pubmed/29204156
http://dx.doi.org/10.1155/2017/6527306

Ejemplares similares